FORM 4	4
--------	---

Check this box if no
longer subject to
Section 16. Form 4 or
Form 5 obligations
may continue. See
Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

02)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person – Ciechanover Isaac E.				0,	mbol	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) (First) (Middle) 611 GATEWAY BOULEVARD, SUITE 900				lonth/Day	/Year)	X Officer (give title below) Other (specify below) Chief Executive Officer			
(Street) SOUTH SAN FRANCISCO, CA 94080			nal F	iled(Month	n/Day/Ye	6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person			
(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned								
1. Title of Security 2. Transaction (Instr. 3) Date (Month/Day/Year)			(A) or Disposed of (D)			Beneficially Owned Following Reported Transaction(s)	Form:	7. Nature of Indirect Beneficial	
	(Month/Day/Year)	Code	V	Amount	(A) or (D)	Price	(Instr. 3 and 4)	Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)
10/13/2016		S <mark>(1)</mark>		2,400	D	\$ 15.91 (2)	404,178	I	See Footnote (3)
10/14/2016		S <mark>(1)</mark>		2,400	D	\$ 16.01 <u>(4)</u>	401,778	I	See Footnote (3)
							549,136	D	
							180,000	Ι	See footnote
	(Middle) D, SUITE 900 A 94080 (Zip) 2. Transaction Date (Month/Day/Year) 10/13/2016	Atara Biotherap (Middle) 3. Date of Earliest D, SUITE 900 10/13/2016 4. If Amendment, A 94080 (Zip) 2. Transaction Date (Month/Day/Year) 10/13/2016 10/13/2016	Atara Biotherapeutics, Ir (Middle) 3. Date of Earliest Transaction D, SUITE 900 10/13/2016 4. If Amendment, Date Origin (Zip) Table I - Non- 2. Transaction 2A. Deemed Date Execution Date, if (Month/Day/Year) (Month/Day/Year) 10/13/2016 S(1)	Atara Biotherapeutics, Inc. [4 (Middle) 3. Date of Earliest Transaction (M 10/13/2016 A 94080 4. If Amendment, Date Original F (Zip) Table I - Non-Deri 2. Transaction Date (Month/Day/Year) 3. Transaction Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 10/13/2016 S(1)	Atara Biotherapeutics, Inc. [ATRA] (Middle) 3. Date of Earliest Transaction (Month/Day 10/13/2016 A 94080 4. If Amendment, Date Original Filed(Month (Zip) Table I - Non-Derivative So 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if (Month/Day/Year) 3. Transaction (Instr. 8) (Month/Day/Year) 2A. Deemed Execution Date, if (Month/Day/Year) 3. Transaction (Instr. 8) 10/13/2016 S(1) 2,400	Atara Biotherapeutics, Inc. [ATRA](Middle) D, SUITE 9003. Date of Earliest Transaction (Month/Day/Year) $10/13/2016$ 4. If Amendment, Date Original Filed(Month/Day/Year)(Zip)2. Transaction Date (Month/Day/Year)2. Transaction Date (Month/Day/Year)2. Transaction Date (Month/Day/Year)2. Transaction Date (Month/Day/Year)10/13/20162. Transaction Date (Month/Day/Year)2. Transaction Date (Month/Day/Year)10/13/201610/13/2016S(1)2.400D	Atara Biotherapeutics, Inc. [ATRA](Middle) D, SUITE 9003. Date of Earliest Transaction (Month/Day/Year) $10/13/2016$ 4. If Amendment, Date Original Filed(Month/Day/Year)4. If Amendment, Date Original Filed(Month/Day/Year)4. If Amendment, Date Original Filed(Month/Day/Year)2. Transaction Date (Month/Day/Year)2. Transaction Date (Month/Day/Year)2. Transaction Date (Month/Day/Year)2. Transaction Date (Month/Day/Year)2. Transaction Date (Month/Day/Year)2. Transaction Date (Month/Day/Year)2. Transaction Date (Month/Day/Year)2. Transaction Date (Month/Day/Year)2. Transaction Date (Month/Day/Year)2. Transaction (Month/Day/Year)2. Transaction Date (Month/Day/Year)2. Transaction (Month/Day/Year)2. Transaction (Month/Day/Year)2. Transaction (Month/Day/Year)3. Transaction (Month/Day/Year)3. Transaction (Date)4. Securities Acquired (Instr. 3, 4 and 5)10/13/2016S(1)2.4002.4003. Transaction (Date)3. Transaction (Date)3. Transaction (Date)3. Transaction (Date)3. Transaction (Date)3. Transaction (Date)3. Transaction (Date)3. Transaction (Date)4. Securities Acquired (Date)4. Securities Acquired (Date)5. Transaction (Date)3. Transaction (Date)3. Transaction (Date)	Atara Biotherapeutics, Inc. $[ATRA]$ (Check all application of the term of te	Atara Biotherapeutics, Inc. [ATRA](Check all applicable)(Middle) D, SUITE 9003. Date of Earliest Transaction (Month/Day/Year)(Check all applicable)A 940804. If Amendment, Date Original Filed(Month/Day/Year)6. Individual or Joint/Group Filing(Check Applic X_{-} Form filed by One Reporting Person Form filed by More than One Reporting Person Form filed by More than One Reporting Person(Zip)Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned2. Transaction Date (Month/Day/Year)3. Transaction (Code (Instr. 3, 4 and 5)5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)6. (Ownership Form: Direct (D) or Indirect (Instr. 4)10/13/2016S(1)2,400D\$ \$ 15.91 (2)10/177810/14/2016S(1)2,400D\$ \$ (6,01 (4)110/14/2016S(1)2,400D\$ \$ (6,01 (4)110/14/2016S(1)2,400D\$ \$ (6,01 (4)510/14/2016S(1)2,400D\$ \$ (6,01 (4)110/14/2016S(1)2,400D\$ \$ (6,01 (4)010/14/2016S(1)11110/14/2016S(1)11110/14/2016S(1)11110/14/2016111110/14/2016111110/14/20161111110/14/2016

Persons who respond to the collection of information SEC 1474 (9contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

	(<i>e.g.</i> , puts, calls, warrants, options, convertible securities)														
1. Title of	2.	3. Transaction	3A. Deemed	4.	5	5. Nun	nber	6. Date Exer	cisable	7. Tit	le and	8. Price of	9. Number of	10.	11. Nature
Derivative	Conversion	Date	Execution Date, if	Transactio	on o	of		and Expirati	on Date	Amo	unt of	Derivative	Derivative	Ownership	of Indirect
Security	or Exercise	(Month/Day/Year)	any	Code	Γ	Deriva	tive	(Month/Day	/Year)	Unde	rlying	Security	Securities	Form of	Beneficial
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	S	Securi	ties			Secur	rities	(Instr. 5)	Beneficially	Derivative	Ownership
	Derivative				A	Acquir	red			(Instr	. 3 and		Owned	Security:	(Instr. 4)
	Security				(.	A) or				4)			Following	Direct (D)	
						Dispos							*	or Indirect	
						of (D)							Transaction(s)	< / </td <td></td>	
					~	Instr.	· · ·						(Instr. 4)	(Instr. 4)	
					4	I, and	5)								
											Amount				
								Date	Evaluation		or				
								Exercisable	Expiration Date	Title	Number				
								Excicisable	Date		of				
				Code V	V ((A)	(D)				Shares				

Reporting Owners

Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Ciechanover Isaac E. 611 GATEWAY BOULEVARD SUITE 900 SOUTH SAN FRANCISCO, CA 94080	Х		Chief Executive Officer	

Signatures

/s/ Tina Gullotta, Attorney-in-Fact for Isaac E. Ciechanover	10/17/2016
Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction pursuant to Rule 10b5-1 Plan adopted March 22, 2016.
- (2) The price in Column 4 is a weighted average sale price. The prices actually received ranged from \$15.70 to \$16.10. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- (3) Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee.
- (4) The price in Column 4 is a weighted average sale price. The prices actually received ranged from \$15.725 to \$16.25. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- (5) Shares are held by the Ciechanover 2015 GRAT, of which the Reporting Person is a trustee.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.